A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.

被引：0
|
作者：
Kim, Hyung-Don
Yoo, Changhoon
Ryu, Min-Hee
Kang, Yoon-Koo
机构：
[1] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[2] Univ Uslan, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11538
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours
    Kim, Hyung-Don
    Yoo, Changhoon
    Ryu, Min-Hee
    Kang, Yoon-Koo
    BRITISH JOURNAL OF CANCER, 2023, 129 (02) : 275 - 282
  • [2] A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours
    Hyung-Don Kim
    Changhoon Yoo
    Min-Hee Ryu
    Yoon-Koo Kang
    British Journal of Cancer, 2023, 129 : 275 - 282
  • [3] Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors
    Yoo, C.
    Ryu, M. -H.
    Na, Y. S.
    Ryoo, B. -Y.
    Park, S. R.
    Kang, Y. -K.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2272 - 2277
  • [4] Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
    Serrano, Cesar
    Leal, Alessandro
    Kuang, Yanan
    Morgan, Jeffrey A.
    Barysauskas, Constance M.
    Phallen, Jillian
    Triplett, Olivia
    Marino-Enriquez, Adrian
    Wagner, Andrew J.
    Demetri, George D.
    Velculescu, Victor E.
    Paweletz, Cloud P.
    Fletcher, Jonathan A.
    George, Suzanne
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7287 - 7293
  • [5] Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib
    Kim, Jae-Joon
    Ryu, Min-Hee
    Yoo, Changhoon
    Beck, Mo Youl
    Ma, Jung Eun
    Kang, Yoon-Koo
    ONCOLOGIST, 2019, 24 (11): : E1212 - E1218
  • [6] Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
    Bauer, S.
    Hilger, R. A.
    Muehlenberg, T.
    Grabellus, F.
    Nagarajah, J.
    Hoiczyk, M.
    Reichardt, A.
    Ahrens, M.
    Reichardt, P.
    Grunewald, S.
    Scheulen, M. E.
    Pustowka, A.
    Bock, E.
    Schuler, M.
    Pink, D.
    BRITISH JOURNAL OF CANCER, 2014, 110 (05) : 1155 - 1162
  • [7] Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
    S Bauer
    R A Hilger
    T Mühlenberg
    F Grabellus
    J Nagarajah
    M Hoiczyk
    A Reichardt
    M Ahrens
    P Reichardt
    S Grunewald
    M E Scheulen
    A Pustowka
    E Bock
    M Schuler
    D Pink
    British Journal of Cancer, 2014, 110 : 1155 - 1162
  • [8] A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors.
    Plummer, R
    Vidal, L
    Perrett, R
    Shaw, H
    Pilkington, M
    Hanwell, J
    Temple, G
    Fong, P
    Amelsberg, A
    Calvert, H
    de Bono, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8990S - 8990S
  • [9] Phase II trial of continuous dosing of regorafenib in patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs) after failure of imatinib and sunitinib.
    Kang, Yoon-Koo
    Kim, Jae-Joon
    Yoo, Changhoon
    Beck, Mo Youl
    Ma, Jungeun
    Ryu, Min-Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors
    Gupta, Sudeep
    Jain, Minish Mahendra
    Maru, Anish
    Nag, Shona Milon
    Somani, Naresh
    Mehta, Ajay O.
    Kulkarni, Sujay
    Acharya, Shivani Anil
    Dhobe, Poornima
    Jadhav, Nitin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345